Skip to content

Study · Randomized controlled trial · 2014

3 results

The effect of liraglutide on endothelial function in patients with type 2 diabetes.

Nandy D, Johnson C, Basu R, Joyner M, Brett J, Svendsen CB, Basu A

Diabetes & vascular disease research11 Sept 2014Cited by 44 (Europe PMC)

PMID25212693 (opens in a new tab)DOI10.1177/1479164114547358 (opens in a new tab)PepBankPUB-25212693
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, acetylcholine-mediated forearm blood flow increased with liraglutide and decreased with placebo, but the between-treatment difference was not significant.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not significantly change blood-vessel response to acetylcholine compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeACh-mediated forearm blood flow at week 12
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    P value
    0.055
    ACh-mediated FBF, liraglutide vs placebo

    Source sentences

    Summary
    At Week 12, ACh-mediated FBF increased with liraglutide and decreased with placebo; however, the between-treatment difference was not significant (p = 0.055).
    1 context sentence
    Summary · context
    This single-centre, 12-week, double-blind, placebo-controlled trial assessed how the human glucagon-like-peptide 1 analogue liraglutide impacted endothelial function in adult patients (n = 49) with type 2 diabetes and no overt cardiovascular disease.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, inhibition of ACh-mediated forearm blood flow after L-NMMA increased with liraglutide and decreased with placebo, without a significant between-treatment difference.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not significantly change the blood-vessel response after L-NMMA compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeInhibition of ACh-mediated forearm blood flow after L-NMMA
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    P value
    0.149
    L-NMMA inhibition, liraglutide vs placebo

    Source sentences

    Summary
    Inhibition of ACh-mediated FBF after L-NMMA infusion increased with liraglutide and decreased with placebo; this between-treatment difference was also not significant (p = 0.149).
    1 context sentence
    Summary · context
    This single-centre, 12-week, double-blind, placebo-controlled trial assessed how the human glucagon-like-peptide 1 analogue liraglutide impacted endothelial function in adult patients (n = 49) with type 2 diabetes and no overt cardiovascular disease.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, no change in forearm blood flow in response to sodium nitroprusside was observed with liraglutide.

    In plain wordsIn adults with type 2 diabetes, liraglutide caused no change in blood flow response to sodium nitroprusside.

    Peptide
    Liraglutide
    Outcome
    No significant changeSodium nitroprusside-mediated forearm blood flow
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No change in FBF was observed with SNP.
    1 context sentence
    Summary · context
    This single-centre, 12-week, double-blind, placebo-controlled trial assessed how the human glucagon-like-peptide 1 analogue liraglutide impacted endothelial function in adult patients (n = 49) with type 2 diabetes and no overt cardiovascular disease.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00620282

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 49Feb 2008 to May 2010

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.